Investor Relations > details

Zensun is Collaborating with The Leibniz-Institut für Alternsforschung-Fritz-Lipmann-Institute.V. to Conduct a Preclinical Study of Neucardin® (recombinant human Neuregulin-1) for The Treatment of Schwannomas


Recently, Zensun and the Leibniz-Institut für Alternsforschung-Fritz-Lipmann-Institute.V. (FLI) announced the collaboration on the preclinical study of Neucardin® (recombinant human Neuregulin-1) for the treatment of schwannomas. Preliminary research from the FLI has shown that recombinant human Neuregulin-1 molecule inhibit the growth of schwannomas in animal models. The two sides will continue to study whether the recombinant human Neuregulin-1 can improve the recovery of nerve function and reduce the growth of schwannomas in the model animals and share the research results. At the same time, Zensun will apply for relevant patents for the research results in the first time to further consolidate the intellectual property protection network related to Neuregulin.

This collaboration is expected to expand the indications for Neucardin® (recombinant human Neuregulin-1) from the cardiovascular area (systolic heart failure, myocardial infarction, etc.) to more therapeutic areas, thereby further expanding the future market potential of Zensun's core product.